Comparative Pharmacology
Head-to-head clinical analysis: BROMFENAC SODIUM versus BROMSITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMFENAC SODIUM versus BROMSITE.
BROMFENAC SODIUM vs BROMSITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever. Specifically, bromfenac is a potent inhibitor of COX-2.
Bromsite (bromfenac ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) 1 and 2, thereby reducing prostaglandin synthesis in ocular tissues.
One drop (0.1 mL) of 0.09% ophthalmic solution (bromfenac 0.9 mg/mL) instilled into the affected eye(s) twice daily beginning 24 hours before cataract surgery and continuing on the day of surgery and for 14 days postoperatively.
1-2 tablets (200-400 mg) orally 3-4 times daily as needed.
None Documented
None Documented
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment; clinical context: short half-life supports twice-daily dosing in ophthalmic use)
Terminal elimination half-life 12–15 hours; prolonged in renal impairment (up to 30 hours).
Renal: ~80% (primarily as unchanged drug and glucuronide conjugate); Biliary/Fecal: ~20%
Primarily renal excretion of unchanged drug (~70%) and glucuronide conjugate (~20%); minor biliary/fecal elimination (~10%).
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID